Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-611 in Healthy Volunteers and Chronic Hepatitis C
NCT03253471Phase 1Terminated
- Sponsor
- Alios BioPharma
- Start
- Jul 2017
- Primary completion
- Sep 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing AL-611 with Placebo (2 arms). Primary endpoints: Incidence and severity of Treatment emergent Adverse events up to 21 days, Physical examination findings up to 21 days and 3 more. Started Jul 2017; status: terminated.
02
Drugs
AL-611
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03253471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253471.